Release date: 30 May 2017
Promoter – Financial Intermediary
CELLNOVO GROUP SA
Investment in Cellnovo's facilities in order to develop its innovative connected all-in-one diabetes management system focused primarily on type 1 diabetes patients
The aim of the project is to scale up production of Cellnovo's novel micro-pump for type 1 diabetes patients and support related capital expenditure for products it plans to bring to the market in the future.
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 41 million
All project activities are expected to be carried out in existing facilities without changing the already authorised scope and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending the EIA Directive 2011/92/EU.
The promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions.
Signed - 7/07/2017
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).